3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Myeloid
3
Sarcoma
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Brain Neoplasms
33
Glioblastoma
32
Melanoma
21
Glioma
19
Neuroblastoma
7
Carcinoma, Renal Cell
6
Carcinoma, Non-Small-Cell Lung
6
Astrocytoma
6
Ependymoma
5
Colorectal Neoplasms
5
Central Nervous System Neoplasms
5
Recurrence
4
Ovarian Neoplasms
4
Medulloblastoma
4
Lymphoma
4
Carcinoma, Hepatocellular
4
Thyroid Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Rhabdomyosarcoma
3
Pancreatic Neoplasms
3
Osteosarcoma
3
Meningioma
3
Lung Neoplasms
3
Gliosarcoma
3
Cholangiocarcinoma
3
Carcinoma, Transitional Cell
3
Vulvar Neoplasms
2
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Interventions
Psychiatric Rehabilitation
5
Melphalan
5
Cyclophosphamide
5
Methylprednisolone
4
Flow Cytometry
4
Busulfan
4
Early Intervention, Educational
3
Antilymphocyte Serum
3
Alemtuzumab
3
fludarabine phosphate
2
Radiotherapy
2
Immunologic Techniques
2
Filgrastim
2
Azacitidine
2
thymoglobulin
1
tanespimycin
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pembrolizumab
1
neratinib
1
ixabepilone
1
fosphenytoin
1
fludarabine
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
cc-486
1
bempegaldesleukin
1
aldesleukin
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
Nivolumab
×
CNS
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts